Robert W. Scully - 21 May 2025 Form 4 Insider Report for Zoetis Inc. (ZTS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 May 2025, 12:14:50 UTC
Prior SEC filing
16 May 2025
Next SEC filing
12 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Brenda Santuccio, as Attorney-in-Fact

Key filing fact

Robert W. Scully filed Form 4 for Zoetis Inc. (ZTS) on 23 May 2025.

Key facts

  • This page summarizes Robert W. Scully's Form 4 filing for Zoetis Inc. (ZTS).
  • 6 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 23 May 2025, 12:14.

Change

  • Previous filing in this sequence was filed on 16 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001352881 Primary reporting owner

SCULLY ROBERT W

Relationship
Director
Address
C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY
Signature
/s/ Brenda Santuccio, as Attorney-in-Fact
Signature date
23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZTS transaction

Common Stock

Options Exercise

Transaction value
Shares
+1,601
Change %
+40%
Price
Shares after
5,555
Date
21 May 2025
Ownership
Direct
Footnotes
F1
ZTS transaction

Common Stock

Options Exercise

Transaction value
Shares
+10,029
Change %
+181%
Price
Shares after
15,584
Date
21 May 2025
Ownership
Direct
Footnotes
F2
ZTS transaction

Common Stock

Options Exercise

Transaction value
Shares
+5,905
Change %
+38%
Price
Shares after
21,489
Date
21 May 2025
Ownership
Direct
Footnotes
F2
ZTS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,590
Date
21 May 2025
Ownership
By trust
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZTS transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-1,601
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,601
Exercise price
Footnotes
F4, F5, F6, F7
ZTS transaction Derivative

Deferred Stock Unit

Options Exercise

Transaction value
$0
Shares
-10,031
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,031
Exercise price
Footnotes
F7, F8, F9, F10
ZTS transaction Derivative

Deferred Stock Unit

Options Exercise

Transaction value
$0
Shares
-5,906
Change %
-100%
Price
$0.000000
Shares after
0
Date
21 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,906
Exercise price
Footnotes
F7, F9, F10, F11
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Robert W. Scully is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 11 footnotes

Footnote F1

Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs) in connection with Mr. Scully's retirement from the Zoetis Board of Directors.

Footnote F2

Acquisition of common stock upon vesting and settlement of deferred stock units (DSUs) in connection with Mr. Scully's retirement from the Zoetis Board of Directors.

Footnote F3

Represents shares held in a trust for the benefit of the reporting person's daughter. The reporting person's spouse is a co-trustee of the trust.

Footnote F4

Represents restricted stock units granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs").

Footnote F5

Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock.

Footnote F6

Each RSU vests and is settled in shares of Zoetis Inc. common stock on the first anniversary of the date of grant, February 19, 2025; subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

Footnote F7

Not applicable.

Footnote F8

Represents deferred stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each a "DSU" and collectively, "DSUs"). The DSUs were fully vested on the date of the grant and settled in shares of Zoetis Inc. common stock upon the reporting person's separation from service as a director at Zoetis.

Footnote F9

Each DSU represents a contingent right to receive one share of Zoetis Inc. common stock.

Footnote F10

Each DSU is settled in shares of Zoetis Inc. common stock upon the reporting person's separation from service as a director of Zoetis Inc.

Footnote F11

Represents deferred stock units granted pursuant to a voluntary deferral under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan, and dividend equivalent units automatically issued thereon (each a "DSU" and collectively, "DSUs"). The DSUs are fully vested and settled in shares of Zoetis Inc. common stock upon the reporting person's separation from service as a director at Zoetis.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .